For the quarter ending 2025-09-30, GNPX made $3,348,318 in revenue. -$3,799,240 in net income. Net profit margin of -113.47%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Depreciation | 0 | 0 | 1,673.25 | |
| Research and development | 2,192,881 | 2,499,495 | 2,633,861.5 | |
| General and administrative | 1,153,032 | 2,182,289 | 2,658,007 | |
| Total operating expenses | 3,345,913 | 4,681,784 | 5,293,541.75 | |
| Operating loss | -3,345,913 | -4,681,784 | -5,293,541.75 | |
| Other income | 2,405 | 6,881 | 15,893.5 | |
| Other financing costs | -455,549 | - | - | |
| Realized and unrealized loss | -183 | 2 | -142.5 | |
| Net loss | -3,799,240 | -4,674,901 | -5,277,790.75 | |
| Deemed dividend related to warrant modification | 0 | 0 | 69,279.75 | |
| Net loss attributable to common stockholders | -3,799,240 | -4,674,901 | -5,347,070.5 | |
| Net loss per share applicable to common stockholders basic and diluted (in dollars per share) | -5 | -0.17 | -1.335 | |
| Weighted average number of common shares basic and diluted (in shares) | 760,502 | 27,593,952 | 1,001,498.5 | |
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)